Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
Status:
Completed
Trial end date:
2016-08-25
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, parallel group Phase 2A/2B study to evaluate the clinical
activity of ASLAN001 in combination with capecitabine compared with lapatinib in combination
with capecitabine in patients with HER2 positive metastatic breast cancer that has failed on
prior trastuzumab therapy.